Objective:To evaluate the efficacy and safety of warfarin for the prevention of central venous catheters-associated(CVCs-associated) thrombosis in patients with cancer systematically via a meta-analysis of randomized controlled trials and(or) clinical controlled trials on warfarin for the prevention of CVCs-associated thrombosis in patients with cancer

and to provide theoretical basis for the clinical prevention of CVCs-associated thrombosis in patients with cancer.Methods:Databases including MEDLINE

OVID

EBSCO

EMBASE

CBM and CNKI were searched

and at the same time

reference retrieval and manual searching were used to acquire basic data.For the literatures which met the inclusion criteria

methodology quality assessment was performed and data information was extracted.A meta-analysis was done by RevMan 5.0.25 statistical software.Results:Seven randomized controlled trials and clinical controlled trials were included.There were six literatures(including 1 522 patients with cancer) about warfarin vs.placebo and one literature(including 45 cancer patients) about warfarin vs.heparin.The results of systematic review were showed as follows:1.In Warfarin vs.placebo

the difference of CVCs-associated thrombosis incidence had statistical significance between the two groups(RR=0.68

95%CI[0.52

0.89];P=0.004).However

the difference of bleeding incidence and mortality rate had no statistical significance

with bleeding incidence(RR=2.12

95%CI[0.82

5.48];P=0.12) and mortality rate(RR=1.01

95%CI[0.58

1.74];P=0.98).2.In Warfarin vs.heparin

the difference of CVCs-associated thrombosis incidence

bleeding incidence and mortality rate had no statistical significance

with the incidence of CVCs-associated thrombosis(RR=0.58

95%CI[0.19

1.79];P=0.35)

bleeding incidence(RR=0.29

95%CI[0.01

6.84];P=0.45)

and mortality rate(RR=0.58

95%CI[0.19

1.79];P=0.35).Conclusion:Warfarin

compared with placebo

is effective and safe in the prevention of CVCs-associated thrombosis in patients with cancer.Warfarin can decrease CVCs-associated thrombosis incidence of patients with cancer effectively and does not increase bleeding incidence or mortality rate.In Warfarin vs.heparin

the efficacy and safety are equal in the prevention of CVCs-associated thrombosis in patients with cancer.But because of scanty related studies

more randomized controlled trials with strict design and large samples are still needed to further raise the intensity of proof.